Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Semaglutide in type 2 diabetes with chronic kidney disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, semaglutide also significantly reduced the rate of eGFR decline (annual slope difference 1•16 mL/min per 1•73 m², 0•86-1•47), MACE (HR 0•82, 0•68-0•98), and all-cause mortality (HR 0•80, 0•67-0•95)”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [26]
In the citing paper
“Treatment with injectable semaglutide 1 mg once weekly reduced the relative risk for the composite primary outcome (ie, ≥50% eGFR decline, eGFR <15 mL/min per 1•73 m², dialysis or transplant, or death due to kidney disease or cardiovascular disease) by 24% compared with placebo (HR 0•76, 0•66-0•88).26”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [26]
In the citing paper
“Moreover, the GLP-1 receptor agonist, semaglutide reduced the risk of a composite kidney end point in a dedicated kidney outcome trial.11”
From The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity (2025) · cites this paper as [11]
In the citing paper
“semaglutide can reduce the progression of chronic kidney disease in patients with and without diabetes and even in those taking SGLT2 inhibitors [12–14].”
From New drugs for the treatment of obesity: do we need approaches to preserve muscle mass? (2025) · cites this paper as [13]
In the citing paper
“Once-weekly treatment with 1 mg semaglutide reduced the risk of the primary composite outcome by 24% and delayed the progression of kidney dysfunction over a period of 4 years (75).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [75]
35 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease
Stevens, P. E., Ahmed, S. B., Carrero, J. J., Foster, B., Francis, A., Hall, R. K., Herrington, W. G., Hill, G., Inker, L. A., Kazancıoğlu, R., et al. (2024) · Kidney International · doi:10.1016/j.kint.2023.10.018 · Cited by 8,530
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Bikbov, B., Purcell, C. A., Levey, A. S., Smith, M., Abdoli, A., Abebe, M., Adebayo, O. M., Afarideh, M., Agarwal, S. K., Agudelo-Botero, M., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30045-3 · Cited by 6,648
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Self-citationLewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618
Self-citationEffect of finerenone on chronic kidney disease outcomes in type 2 diabetes
Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Rossing, P., Kolkhof, P., Nowack, C., Schloemer, P., Joseph, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2025845 · Cited by 2,935
Self-citationEmpagliflozin in Patients with Chronic Kidney Disease
The EMPA-KIDNEY Collaborative Group (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2204233 · Cited by 2,754
Cardiovascular events with finerenone in kidney disease and type 2 diabetes
Pitt, B., Filippatos, G., Agarwal, R., Anker, S. D., Bakris, G. L., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Schloemer, P., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110956 · Cited by 1,814
Self-citation
Cited by
Items 401–500 of 1,871
Kobayashi, M., Bozkurt, B., Myhre, P. L., López‐Azor, J. C., Guzik, M., Iwanek, G., Baudry, G., Marcos, M. C., Miró, Ò., Dauw, J., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.70079 · Cited by 11
Wang, J., Lee, C., Ko, W., Wu, L., & Chang, C. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112324 · Cited by 11
Sleep-Related Disorders in Patients with CKD and Kidney Transplant Recipients
Vendeville, N., Mucsi, I., & Molnar, M. Z. (2025) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000728 · Cited by 12
Yang, M., Kondo, T., Dewan, P., Desai, A. S., Lam, C. S. P., Lefkowitz, M. P., Packer, M., Rouleau, J. L., Vaduganathan, M., Zile, M. R., et al. (2025) · Circulation Heart Failure · doi:10.1161/circheartfailure.124.011598 · Cited by 14
Liraglutide vs Semaglutide vs Dulaglutide in Veterans With Type 2 Diabetes
Derington, C. G., Sarwal, A., Wei, G., Hartsell, S. E., Throolin, M. J., Singh, R., Nevers, M. R., Zhang, C., Katkam, N., Takyi, A., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.37297 · Cited by 13
Skaarup, K. G., Johansen, N. D., Brandi, L., Lindhardt, M. K., Bech, J. N., Svensson, M. H. S., Kristensen, T., Thuesen, A. D., Knudsen, M. G., Kampmann, J. D., et al. (2025) · Circulation · doi:10.1161/circulationaha.125.075403 · Cited by 12
Clinical trial designs of emerging therapies for diabetic kidney disease (DKD)
Singh, A. K., Farag, Y. M. K., Zheng, Z., & Bakris, G. L. (2024) · Postgraduate Medicine · doi:10.1080/00325481.2024.2377529 · Cited by 10
“…therapies include sodium-glucose transport protein-2 inhibitors (SGLT2i, i.e. empagliflozin, dapagliflozin, and canagliflozin) [4–6], non-steroidal mineralocorticoid receptor antagonist (nsMRA, i.e. finerenone) [7–9], and glucagon-like peptide-1 receptor agonist (GLP-1RA, i.e. semaglutide) [10,11].”
Self-citationNeumiller, J. J., Herrin, J. S., SWARNA, K. S., Polley, E. C., Galindo, R. J., Umpierrez, G. E., Deng, Y., Ross, J. S., Mickelson, M. M., & McCoy, R. G. (2024) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000587 · Cited by 13
Obesity and Chronic Kidney Disease: The Dual Epidemic in Cardiovascular Health
Grant, C. H., & Bell, S. (2025) · European Cardiology Review · doi:10.15420/ecr.2025.33 · Cited by 12
Kishimori, T., Kato, T., Wada, A., Tani, A., Yamaji, R., Koike, J., Iwasaki, Y., Matsumoto, T., Yagi, T., & Okada, M. (2025) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcaf065 · Cited by 8
Rosenstock, J., Billings, L. K., Gajria, R., Giorgino, F., Johansen, N. B., Klein, K. R., Thamattoor, U. K., Buse, J. B., & Jain, A. B. (2026) · The Lancet · doi:10.1016/s0140-6736(26)01022-6 · Cited by 15
Glucagon-like peptide-1 medicines and cancer
Yabut, J. M., & Drucker, D. J. (2026) · Nature Cancer · doi:10.1038/s43018-025-01110-1 · Cited by 16
The Therapeutic Potential of Glucagon-like Peptide 1 Receptor Agonists in Traumatic Brain Injury
Harej, A., Pilipović, K., Belančić, A., Juretić, L., Vitezić, D., & Mršić‐Pelčić, J. (2024) · Pharmaceuticals · doi:10.3390/ph17101313 · Cited by 11
“Very recently, a FLOW trial was published, and subcutaneous semaglutide also demonstrated a reduction in the risk of clinically important kidney outcomes and cardiovascular death in patients with diabetes mellitus type 2 and chronic kidney disease [49].”
BackgroundChronic Kidney Disease in Patients With Heart Failure With a Preserved Ejection Fraction
Packer, M., Testani, J. M., Butler, J., Zannad, F. M., Lam, C. S. P., Vaduganathan, M., Fang, J. C., & Borlaug, B. A. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.08.086 · Cited by 15
Kim, Y. C., Das, V., Kanoo, S., Yao, H., Stanford, S. M., Bottini, N., Karihaloo, A. K., & Vallon, V. (2024) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00231.2024 · Cited by 9
Kugathasan, L., Aronson, Y., Sridhar, V. S., Ni, H., Ouimet, J.-P., Limonte, C. P., Sarma, S., & Cherney, D. Z. I. (2025) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2025.2537446 · Cited by 9
“…trial to investigate semaglutide in 3508 participants with T2D and CKD (defined as eGFR of 50–75 mL/min/1.73 m 2 and UACR of 300–5000 mg/g, or eGFR of 25–50 mL/min/1.73 m 2 and UACR of 100–5000 mg/g), up-titrated to 1 mg once weekly on a background of RAS inhibition for a median of 3.4 years [10].”
InfluentialAla, M., & Aleaba, M. M. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-024-02459-3 · Cited by 12
Why do obesity drugs seem to treat so many other ailments?
Lenharo, M. (2024) · Nature · doi:10.1038/d41586-024-03074-1 · Cited by 17
Blum, M. F., Mehta, S., Surapaneni, A., Carrero, J. J., Zhang, D. “., Inker, L. A., Horwitz, L. I., Blecker, S., Shin, J., & Grams, M. E. (2025) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000902 · Cited by 9
Residual Renal Risk in Diabetic Nephropathy Despite Contemporary Therapies
Speeckaert, R., Delrue, C., & Speeckaert, M. M. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15030921 · Cited by 17
Duhan, S., Kurpad, K. P., Keisham, B., Shtembari, J., Brener, A., Kanakadandi, U. B., Garg, A., Adoni, N. A., & Mehta, S. S. (2025) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.133604 · Cited by 8
Lezama, C. A. A., Ramos, J., Eguizábal, D. A. A., Ovando, X. S. S., Villagran, J., & Caiza, C. J. M. (2025) · Cureus · doi:10.7759/cureus.85813 · Cited by 28
Anumas, S., & Inagi, R. (2025) · Nephrology · doi:10.1111/nep.70098 · Cited by 12
“In patients with CKD, the FLOW trial demonstrated that subcutaneous semaglutide also reduced cardiovascular risk and slowed CKD progression, likely through anti-inflammatory, antioxidant and antifibrotic mechanisms [117, 118].”
Gallwitz, B., Aberle, J., Birkenfeld, A. L., Fritsche, A., Kellerer, M., Klein, H. H., Landgraf, R., Müller‐Wieland, D., Müssig, K., Nauck, M. A., et al. (2024) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2312-0315 · Cited by 9
Using Second-Generation Anti-Obesity Medications
Schmitz, S. H., & Aronne, L. J. (2024) · Diabetes Spectrum · doi:10.2337/dsi24-0002 · Cited by 11
A FIDELITY Analysis on Finerenone With SGLT-2i and GLP-1RA in CKD
Singh, A. K., Anker, S. D., Pitt, B., Rossing, P. R., Ruilope, L. M., Ahlers, C., Farag, Y. M. K., Lambelet, M., BRINKER, M. D., Rohwedder, K., et al. (2025) · Kidney International Reports · doi:10.1016/j.ekir.2025.10.032 · Cited by 15
Self-citationLi, P. K., Cheung, M., Chow, K., Leung, M. K. W., Lim, L., Lui, J. N. M., Luk, A. O. Y., Manski-Nankervis, J.-A., Seidu, S., Tandon, N., et al. (2025) · Kidney International Reports · doi:10.1016/j.ekir.2025.06.010 · Cited by 8
Water and electrolyte abnormalities in novel pharmacological agents for kidney disease and cancer
Terashita, M., Yazawa, M., Murakami, N., Nishiyama, A., Electrolyte Winter Seminar Collaborative Group, Fujimaru, T., Fujita, Y., Hirose, K., Kawada, K., Monkawa, T., et al. (2025) · Clinical and Experimental Nephrology · doi:10.1007/s10157-025-02635-6 · Cited by 8
“GLP-1RAs may reduce major adverse cardiovascular events and improve renal function in patients with T2DM and kidney diseases [69, 70].”
Xie, Y., Choi, T., & Al-Aly, Z. (2026) · BMJ Medicine · doi:10.1136/bmjmed-2025-002150 · Cited by 8
Effect of incretin-based therapies on blood pressure: a systematic review and meta-analysis
Basile, C., Merolla, A., Mancusi, C., Luca, C. D., Fucile, I., Canonico, M. E., Giugliano, G., Orso, F., Morisco, C., & Esposito, G. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf560 · Cited by 17
Seddio, A. E., Vasudevan, R. S., Gouzoulis, M. J., Ansah-Twum, J. K., Grauer, J. N., & Rubin, L. E. (2025) · The Journal of Arthroplasty · doi:10.1016/j.arth.2025.08.003 · Cited by 14
Weltman, M. R., Lavenburg, L.-M. U., Han, Z., Alghwiri, A. A., Mosslemi, M., Rollman, B. L., Fischer, G. S., Nolin, T. D., Yabes, J. G., & Jhamb, M. (2024) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000544 · Cited by 13
“41,42 All these factors may have contributed to lack of effect of K-CHAMP intervention on CKD progression/kidney failure in our trial.”
The Impact of Glucagon-like Peptide-1 Receptor Agonists on Erectile Function: Friend or Foe?
Kounatidis, D. C., Vallianou, N. G., Rebelos, E., Vallianou, K., Diakoumopoulou, E., Makrilakis, K., & Tentolouris, N. (2025) · Biomolecules · doi:10.3390/biom15091284 · Cited by 16
“…use reduced the risk of a composite kidney-specific outcome, including progression to kidney failure or a sustained ≥ 50% decline in estimated glomerular filtration rate (eGFR), by 21% (HR: 0.79; 95% CI: 0.66–0.94) and attenuated the annual decline in eGFR by 1.16 mL/min/1.73 m 2 ( p < 0.001) [76].”
InfluentialOstrominski, J. W., Wagholikar, K. B., Olsson, K., Ünlü, O., Zelle, D., Kumar, S., Smith, A. M., Toliver, J. C., Michalak, W., Fabricatore, A. N., et al. (2024) · Obesity · doi:10.1002/oby.24186 · Cited by 8
Sonne, N., Roque, M., Zachariassen, L. F., Porsgaard, T., Pors, S. E., Cavalera, M., Jones, C., Osborn, O., Thorbek, D. D., Riis, M. L., et al. (2026) · EBioMedicine · doi:10.1016/j.ebiom.2026.106121 · Cited by 9
Zupec, J. F., Munger, R., Scaletta, A., & Quinn, D. H. (2025) · Nutrition in Clinical Practice · doi:10.1002/ncp.11279 · Cited by 9
Chee, Y. J., & Dalan, R. (2024) · Biomedicines · doi:10.3390/biomedicines12071386 · Cited by 10
“With the increasing use of GLP-1 RA, long-term follow-up of data will provide more definitive evidence regarding cancer risks with GLP-1 RA.”
BackgroundAntiobesity Medications for Older Adults—the New, the Good, the Bad, and the Unknown
Pendrey, A., & Sevilla‐Martir, J. (2025) · Obesity · doi:10.1002/oby.70029 · Cited by 11
Olsen, E., Jamerson, K., Schmieder, R. E., Søraas, C. L., Mariampillai, J. E., Mancia, G., Kjeldsen, S. E., Heimark, S., Mehlum, M. H., Liestøl, K., et al. (2024) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2024.12.021 · Cited by 14
Alhomoud, I. S., Wheeler, S. E., & Dixon, D. L. (2025) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2025-0038 · Cited by 14
Gholami, M., Balajam, N. Z., Rakhsha, S. S., Sajjadi‐Jazi, S. M., Shafiee, G., & Heshmat, R. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01604-w · Cited by 9
“The study demon - strated that semaglutide significantly diminished the risk of kidney-related events and slowed the progression of kidney dysfunction, suggesting its potential in preventing further kidney damage in patients with diabetes and chronic kidney disease [27, 28].”
Guidelines on primary healthcare for type 2 diabetes in China, 2025
Jia, W., Zhu, D., Guo, L., Chen, L., Cai, C., & Song, J. (2025) · Family Medicine and Community Health · doi:10.1136/fmch-2025-003765 · Cited by 11
Riehl-Tonn, V. J., Medak, K. D., Rampersad, C., MacPhee, A., & Harrison, T. G. (2024) · Canadian Journal of Kidney Health and Disease · doi:10.1177/20543581241290317 · Cited by 12
“12 Another study called REMODEL is underway, which is designed to understand how GLP-1RAs mechanistically work on the kidneys in individuals with CKD and T2D.”
BackgroundFabre, L., Pedregosa-Miguel, J. F., & Rangel, É. B. (2024) · Diabetology · doi:10.3390/diabetology5040030 · Cited by 8
Combination Therapy with SGLT2 Inhibitors and GLP-1 Receptor Agonists for Diabetic Kidney Disease
Tang, M., Morieri, M. L., Kalim, S., & Doria, A. (2025) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000620 · Cited by 8
Delaying Progression of Chronic Kidney Disease
Song, R. M., Alexander, J. T., & Prochaska, M. (2025) · JAMA · doi:10.1001/jama.2025.9532 · Cited by 10
Sillassen, C. D. B., Petersen, J. J., Faltermeier, P., Yucel, D., Siddiqui, F., Andersen, R. K., Graever, L., Bjerg, J. L., Kamp, C. B., Grand, J., et al. (2025) · BMC Medicine · doi:10.1186/s12916-025-04486-0 · Cited by 10
“The assessment time points were 17 weeks [54] [48], 3.4 years (mean) [57], and 47.5 months (mean) [80] after randomization.”
InfluentialA Brain Reward Circuit Inhibited By Next-Generation Weight Loss DrugsPreprint
Godschall, E., Güngül, T. B., Sajonia, I. R., Buyukaksakal, A. K., Li, O. D.-A., Ogilvie, S., Keeler, A. B., Tian, G., Koita, O., Shi, Y., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.12.628169 · Cited by 8
Glycemic therapies and the risk of gastrointestinal adverse events in veterans with type 2 diabetes
Sarwal, A., Singh, R., Wei, G., Shen, J., Nevers, M. R., Hartsell, S. E., Derington, C. G., Takyi, A., Chakravartula, A. R., Katkam, N., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16642 · Cited by 8
Dietary and pharmacological energy restriction and exercise for healthspan extension
Cagigas, M. L., Ciutiis, I. D., Masedunskas, A., & Fontana, L. (2025) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.04.001 · Cited by 15
Ardehali, H. (2024) · Journal of Clinical Investigation · doi:10.1172/jci186225 · Cited by 9
“The FLOW trial showed that semaglutide reduces the risk of clinically important kidney outcomes and death from CV disease in patients with diabetes and chronic kidney disease (26).”
BackgroundFishkin, A., Rozenberg, A., Schechter, M., Sehtman-Shachar, D. R., Aharon‐Hananel, G., Leibowitz, G., Yanuv, I., & Mosenzon, O. (2025) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70066 · Cited by 12
“These findings can be explained by the robust kidney protective effects of SGLT2i [4, 5].”
InfluentialMark, P. B., Sousa‐Amorim, E. D., Eriksson, A. L., Leonsson‐Zachrisson, M., Guzman, N. J., Miller, M. T., Jiang, Y., & Heerspink, H. J. L. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf119 · Cited by 12
Gasoyan, H., Schulte, R. J., Boyer, C., Casacchia, N. J., Butsch, W. S., Le, P. N. B., Aminian, A., Griebeler, M. L., Burguera, B. G., & Rothberg, M. B. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70660 · Cited by 13
“Treatment with semaglutide also prevents cardiovascular events, particularly in patients with established atherosclerotic cardiovascular disease [9] and slows progression of kidney disease in those with T2D and chronic kidney disease [10].”
Zhou, J., Husain, M., Li, Y., Liu, W., Shen, Z., Vilsbøll, T., & Ge, J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16621 · Cited by 10
“…Disease; NCT03819153) demonstrated that OW s.c. semaglutide 1.0 mg reduced the risk of major kidney disease events, MACE, and all-cause death by 24%, 18%, and 20%, respectively, versus placebo in people with T2D and CKD. 19 The mechanism of action of semaglutide in CVD and CKD remains unclear.”
InfluentialGLP-1 receptor agonists in heart failure
Vaduganathan, M. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01598-8 · Cited by 8
Zoungas, S., D’Alessio, D. A., Pavo, I. J., Bhatt, D. L., Buse, J. B., Prato, S. D., Kahn, S. E., Lincoff, A. M., McGuire, D. K., Nauck, M. A., et al. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00032-x · Cited by 17
“…or greater reduction in eGFR, end-stage kidney disease, or death from kidney disease 10,17 (composite kidney outcome 3); and time to occurrence of persistent 50% or greater reduction in eGFR, end-stage kidney disease, or death from kidney or cardiovascular disease 27 (composite kidney outcome 4).”
Kidney and Survival Outcomes with Semaglutide by CKD Severity in the FLOW Trial
Tuttle, K. R., Mann, J. F. E., Mayrdorfer, M., Rayner, B. L., Pugliese, G., Pratley, R. E., Perkovic, V., Mahaffey, K. W., Kashihara, N., Jeppesen, O. K., et al. (2026) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000974 · Cited by 15
“6,22 Lower eGFR and higher albuminuria independently and additively increase risks of cardiovascular and all-cause deaths.”
Self-citationGlucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs): A Pan-Steatotic Liver Disease Treatment?
Chrysavgis, L., Mourelatou, N. G., & Cholongitas, Ε. (2025) · Biomedicines · doi:10.3390/biomedicines13071516 · Cited by 10
Gandhi, A., Bhatt, N., & Parhizgar, A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14217678 · Cited by 14
Morales, E., Martin, W. P., Bevc, S., Jenssen, T. G., Miglinas, M., & Trillini, M. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf069 · Cited by 8
“It should be noted, however, that there was no difference in the acute 12-week eGFR slope between the semaglutide and placebo arms in the FLOW RCT [18 ], suggesting that changes in glomerular haemody-namics may be less pronounced than those observed after SGLT2i initiation.”
InfluentialDutta, D., Mahajan, K., Kamrul-Hasan, A. B. M., Mahajan, N., Sharma, M., & Vohra, S. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70391 · Cited by 12
How do drugs such as Ozempic work for weight loss . . . and everything else?
Guenot, M. (2024) · BMJ · doi:10.1136/bmj.q1767 · Cited by 7
Effects of Semaglutide on CKD in Patients With Type 2 Diabetes
Kotwal, S. S., & Perkovic, V. (2024) · Kidney International Reports · doi:10.1016/j.ekir.2024.11.1365 · Cited by 8
Self-citationAddressing unmet needs for chronic kidney disease treatment in type 1 diabetes: A review
Tuttle, K. R., Ji, L., Mathieu, C., & Rosen, J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70180 · Cited by 8
Self-citationNagpal, S., & Gibson, G. C. (2024) · medRxiv · doi:10.1101/2024.07.29.24311065 · Cited by 7
Zhang, J., Guan, X., Kong, M.-W., Xia, M., Yu, Y., & Zhang, C. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156433 · Cited by 9
The National Psoriasis Foundation Primer on GLP-1 Receptor Agonists in Psoriasis: A Review
Sheth, S., Merola, J. F., Weber, B. N., Prussick, R. B., Yeung, J., Liu, C., Glick, B. P., Reddy, S. M., Cook-Bolden, F. E., Wallace, E. B., et al. (2026) · JAMA Dermatology · doi:10.1001/jamadermatol.2026.0859 · Cited by 17
Soliman, A. R., Saleem, H. M. E., Meligi, A. A. H. E., Naguib, M., Mohamed, R. S., Abdelaziz, G. R., Rakha, M., Abdelghaffar, S., Hamed, A. E., Hammad, H., et al. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01564-w · Cited by 10
“Patients treated with semaglutide experienced a 24% reduction in the risk of the composite primary endpoint, which encompassed kidney outcomes and mortality related to renal and/or cardiovascular (CV) causes, in comparison to those receiving a placebo [154].”
Mertens, J., Winter, H. T. D., Dirinck, E. L., Francque, S., & Block, C. E. M. D. (2025) · Diabetes Technology & Therapeutics · doi:10.1177/15209156251362497 · Cited by 12
Gera, A., Latif, F., Borra, V., Naz, S., Mittal, V., Ayoobkhan, F. S., Kumar, T., Wajid, Z., Deb, N., Prasad, T., et al. (2025) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2025.101638 · Cited by 20
Small-Molecule GLP-1 Receptor Agonists: A Promising Pharmacological Approach
Șeremet, O. C., Pușcașu, C., Andrei, C., Nițulescu, G., Zbârcea, C. E., & Olaru, O. T. (2025) · Medicina · doi:10.3390/medicina61111902 · Cited by 12
“This approval is based on results from the FLOW trial, which demonstrated that semaglutide significantly lowers the incidence of major renal and cardiovascular events, representing an important advancement in the management of patients with diabetes and concomitant renal impairment [25].”
Yau, K., Cherney, D. Z. I., & Odutayo, A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70044 · Cited by 9
Approaches to patients with obesity and CKD: focus on nutrition and surgery
Bellizzi, V., Annunziata, G., Albanese, A., D’Alessandro, C., Garofalo, C., Foletto, M., Barrea, L., Cupisti, A., Zoccali, C., & Nicola, L. D. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae291 · Cited by 13
Epidemiology of cardiovascular–kidney–metabolic syndrome
Mavromatis, L. A., & Grams, M. E. (2026) · Nature Reviews Nephrology · doi:10.1038/s41581-026-01078-w · Cited by 14
Dobbie, L. J., Tolvanen, L., Alves, D., Baker, J. L., Bez, N. S., Birney, S., Bogl, L. H., Brown, A., Bullo, M., Clare, K., et al. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00122-1 · Cited by 8
Obesity and Risk of Kidney Outcomes in Heart Failure With Preserved Ejection Fraction
Lassen, M. C. H., Ostrominski, J. W., Claggett, B. L., Neuen, B. L., Beldhuis, I. E., Butt, J. H., Biering‐Sørensen, T., Desai, A. S., Lewis, E. F., Jhund, P. S., et al. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.03.042 · Cited by 11
Repurposing metabolic drugs as anti-inflammatory agents
Hogan, A. E., Davis, C., Jenkins, B. J., Jones, N., & O'Shea, D. B. (2025) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.07.003 · Cited by 15
Song, S., Ni, J., Sun, Y., Pu, Q., Zhang, L., Yan, Q., & Yu, J. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1459752 · Cited by 13
Lan, N. S. R., Hiew, J., Ferreira, I., Ritter, J. C., Manning, L. A., Fegan, P. G., Hamilton, E. J., & Dwivedi, G. (2025) · Physiological Reports · doi:10.14814/phy2.70415 · Cited by 7
“…outcomes in patients with type 2 diabetes and al-buminuric CKD. (Bakris et al., 2020; Heerspink et al., 2020; Herrington et al., 2023; Perkovic et al., 2019, 2024; Pitt et al., 2021) Importantly, these therapies have mechanisms of action that target interrelated haemodynamic,…”
Benefits of Glucagon-like Peptide-1 Receptor Agonists After Kidney Transplantation
Sahi, S. S., Valencia, O. A. G., Na, J., Lemke, A. I., Duffy, D. J., Smith, B. H., Navrátil, P., Budhiraja, P., Diwan, T. S., Issa, N. S., et al. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.02.020 · Cited by 7
Kittleson, M. D., Panjrath, G. S., Bates, K., Breathett, K. K., Dixon, D. L., Januzzi, J. L., & Mohammed, S. F. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.06.018 · Cited by 25
Uma, A., Sivaraman, S., Manoharan, R., & Periasamy, P. (2025) · Journal of Pharmacy And Bioallied Sciences · doi:10.4103/jpbs.jpbs_1059_25 · Cited by 9
“Initial eGFR dip, long‑term benefits [5] GLP‑1 Ras Potential renal benefits; cautious use in CKD Slows eGFR decline Increased hypoglycemia risk in some [6]”
Wade, F. G., Lentine, K. L., Turk, D., Kirbach, K., Knobloch, T., Schnitzler, M. A., Qureshi, K., Syn, W., & Fleetwood, V. A. (2025) · Clinical Transplantation · doi:10.1111/ctr.70344 · Cited by 9
“While evidence supports the use of semaglutide for patients with T2DM and chronic kidney disease (CKD), there is little efficacy and safety data for semaglutide use in patients with ESKD on dialysis [8].”
Nakhleh, A., Khazim, K., & Shehadeh, N. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14228209 · Cited by 7
“This benefit was consistent across all CKD severity categories defined by estimated glomerular filtration rate (eGFR) or albumin-uria, and was accompanied by clinically relevant improvements in glycemic control, body weight, and blood pressure at 104 weeks [6].”
Watanabe, S., Nakayama, M., Yokoo, T., Sanada, S., Ubara, Y., Komatsuda, A., Asanuma, K., Suzuki, Y., Konta, T., Kazama, J. J., et al. (2025) · Science Advances · doi:10.1126/sciadv.adw3934 · Cited by 12
Her, Q. L., Wang, T., Stürmer, T., Buse, J. B., Funk, M. J., Pate, V., & Webster‐Clark, M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70002 · Cited by 11
Neff, G. W. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70148 · Cited by 13
“131 Whether GCGR agonism on top of GLP-1 receptor agonism will result in additional cardiovascular or kidney benefits with dual agonists — or adverse cardio-kidney effects — remains to be determined.”
Hong, B., Kim, H., Lee, D., & Kim, K. (2025) · Pharmaceuticals · doi:10.3390/ph18071058 · Cited by 12
“Semaglutide has also shown promise in improving renal outcomes in patients with DM and chronic kidney disease, as indicated by the FLOW trial results [43], and in resolving non-alcoholic steatohepatitis without worsening fibrosis in some patients [44].”
Diallo, A., Villard, O., Carlos‐Bolumbu, M., Duc, P., & Galtier, F. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16561 · Cited by 9
Chiang, C., Wang, K.-L., Cheng, H., Chao, T., & Sung, S. (2025) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000001263 · Cited by 12
Kueh, M. T. W., Yeo, J. Q., Chen, Y., Chua, N. Y. Z., Koh, H. L., Khaw, S. P., Jabbar, H., Wang, J., Lee, K. S. S., Chin, Y. H., et al. (2026) · Liver International · doi:10.1111/liv.70747 · Cited by 17
“…CKD with type 2 diabetes, most notably in the phase 3 Evaluate Renal Function with Semaglutide Once Weekly (FLOW) trial, in which subcutaneous semaglutide (at a dose of 1.0 mg weekly) significantly reduced the risk of clinically important kidney outcomes and CVD mortality compared to placebo [124].”
InfluentialThe glomerular endothelial glycocalyx as a therapeutic target in proteinuric kidney disease
Gamez, M., Ramnath, R. D., Butler, M. J., Foster, R. R., & Satchell, S. C. (2025) · Nature Reviews Nephrology · doi:10.1038/s41581-025-01028-y · Cited by 17
“Glucagon-like peptide 1 (GLP1) agonists also reduce proteinuria and improve kidney outcomes in DKD 152,153 .”
Ho, L. T., Fang, Y., Hsu, P.-S., Wang, J., & Tsai, M. (2025) · Scientific Reports · doi:10.1038/s41598-025-19657-5 · Cited by 13
Advancements in Pharmacotherapy for Diabetic Kidney Disease: A Systematic Review
Zhang, H., Chen, J., Wang, N., Chen, W., Xu, Y., & Gui, D. (2025) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70077 · Cited by 9
“These outcomes include serious kidney complications, kidney failure (including the need for dialysis, a transplant, or an eGFR 15 mL/min/ 1.73 m 2 ), a ≥ 50% decrease in eGFR, and mortality linked to kidney or cardiac issues [6].”
InfluentialMaruyama‐Sakurai, K., Tachimori, H., Saito, E., Kohsaka, S., Segawa, Y., Miyata, H., & Igarashi, A. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15832 · Cited by 8
“46 guidance and to prevent it from advancing to renal failure or dialysis.”
Siniukovich, A., Travlos, C. K., Freedman, S., Mavrakanas, T. A., & Gariani, K. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01831-4 · Cited by 14
“…(persistent eGFR 15 mL/min/1.73 m² or initiation of chronic renal replacement therapy), ≥ 50% eGFR decline from baseline, or death from renal or cardiovascular causes, thus showing for the first time a beneficial impact of GLP-1 RAs on an even more clinically significant renal outcome [13].”
InfluentialConnolly, D. L., Collins, E., Ren, H., Ming, S. W. Y., Davidson, J. A., & Bain, S. C. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01715-w · Cited by 9
“Furthermore, recent results from the FLOW trial (NCT03819153) demonstrated that subcutaneous semaglutide was able to reduce the risk of MACE by 18% compared with placebo in patients with T2D and comorbid kidney disease [28].”
Cowart, K., & Carris, N. W. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16502 · Cited by 7
β-Mangostin Alleviates Renal Tubulointerstitial Fibrosis via the TGF-β1/JNK Signaling Pathway
Huang, P.-Y., Juan, Y.-H., Hung, T., et al. (2024) · Cells · doi:10.3390/cells13201701 · Cited by 7
Metadata
- Authors
- Perkovic, V., Tuttle, K. R., Rossing, P., Mahaffey, K. W., Mann, J. F. E., Bakris, G., Baeres, F. M. M., Idorn, T., Bosch-Traberg, H., Lausvig, N. L., & Pratley, R.
- Affiliations
- University of Copenhagen (DK)
- Novo Nordisk A/S, Søborg, Denmark.
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-07-11
- Volume
- 391
- Issue
- 2
- Pages
- 109-121
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4398781461
- Cited by
- 2,099
- References
- 23
- Citations by year
- 2026: 953 · 2025: 863 · 2024: 281
- FWCI
- 551.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Digital Access to Libraries (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Funders
- Novo Nordisk A/S
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- semaglutide, chronic kidney disease, type 2 diabetes, renal failure, estimated glomerular filtration rate decline, cardiovascular mortality, albuminuria, GLP-1 receptor agonists, renal protection, cardiovascular outcomes, albumin-creatinine ratio, kidney transplantation, dialysis, anemia of chronic kidney disease, diabetic nephropathy, SGLT2 inhibitors
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Double-Blind Method, Glucagon-Like Peptides, Female, Glomerular Filtration Rate, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Male, Middle Aged, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.